MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

BIND Therapeutics Company Profile (NASDAQ:BIND)

Consensus Ratings for BIND Therapeutics (NASDAQ:BIND) (?)
Ratings Breakdown: 4 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $7.44 (1,857.24% upside)

Analysts' Ratings History for BIND Therapeutics (NASDAQ:BIND)
Show:
DateFirmActionRatingPrice TargetActions
5/2/2016Stifel NicolausDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2016Cowen and CompanyDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2016OppenheimerDowngradeMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$9.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2014Credit SuisseDowngradeOutperform -> Neutral$20.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for BIND Therapeutics (NASDAQ:BIND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/9/2016Q116($0.55)($0.61)$3.83 million$1.87 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415($0.49)($0.37)$3.35 million$6.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/2/2015Q315($0.52)($0.49)$3.14 million$2.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.51)($0.51)$3.88 million$2.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.51)($0.44)$2.67 million$4.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2015Q414($0.40)($0.51)$6.00 million$3.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014($0.31)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.60)($0.51)$2.20 million$2.46 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2014($0.49)($0.51)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/25/2014($0.41)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313($0.67)($2.70)$1.66 million$4.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for BIND Therapeutics (NASDAQ:BIND)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.61)($0.58)($0.60)
Q2 20162($0.48)($0.46)($0.47)
Q3 20162($0.48)($0.46)($0.47)
Q4 20162($0.49)($0.47)($0.48)
(Data provided by Zacks Investment Research)
Dividend History for BIND Therapeutics (NASDAQ:BIND)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for BIND Therapeutics (NASDAQ:BIND)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
9/25/2013Noubar AfeyanDirectorBuy20,000$15.00$300,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2013Polaris Venture Management Co.Major ShareholderBuy26,000$15.00$390,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for BIND Therapeutics (NASDAQ:BIND)
DateHeadline
06/28/16 07:18 AMCovering the Bases on BIND Therapeutics, Inc. (NASDAQ:BIND): Where is the Stock Going? - Press Telegraph
06/25/16 05:50 AMHow Many BIND Therapeutics Inc (NASDAQ:BIND)'s Analysts Are Bearish? - Engelwood Daily
06/24/16 02:51 PMNew Broker Ratings For BIND Therapeutics, Inc. (NASDAQ:BIND) - FTSE News
06/23/16 04:23 PMPre-market Equity Watch on Biotechnology -- Infinity Pharma, Nektar Therapeutics, Aralez Pharma, and BIND Therapeutics
06/22/16 07:58 PMBIND THERAPEUTICS, INC : Submission of Matters to a Vote of Security Holders (form 8-K)
06/22/16 03:06 PMBIND THERAPEUTICS, INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/19/16 02:44 PMThis Weeks Broker Views For BIND Therapeutics, Inc. (NASDAQ:BIND) - Fiscal Standard
06/18/16 07:33 AMBIND Therapeutics Announces Resignation of Directors Affiliated with Polaris Partners - Business Wire (press release)
06/17/16 02:46 PMBIND Therapeutics (BIND) Announces Resignation of Polaris-Affiliated Directors - StreetInsider.com
06/17/16 02:46 PMBRIEF-Bind Therapeutics announces some board members' resignations - Reuters
06/17/16 10:47 AMAustralian Insurance Industry Governance, Risk and Compliance Report 2016 - Research and Markets
06/17/16 10:47 AMBIND Therapeutics Announces Resignation of Directors Affiliated with Polaris Partners
06/15/16 02:53 PMDiffuse Large B-Cell Lymphoma - Pipeline Review, H1 2016 - Research and Markets
06/09/16 11:44 AMNew Report Available: Kinesin Spindle Protein (KSP or Eg5) - Pipeline Review, H1 2016
06/08/16 11:21 AMBIND Therapeutics, Inc. (NASDAQ:BIND) Upcoming Earnings: What matter for investors? - iStreetWire
06/03/16 08:55 PMBIND Therapeutics, Inc. (NASDAQ:BIND) Stock Update & Estimates - Stock Tick Tock
06/03/16 08:55 PMBIND Therapeutics, Inc. (NASDAQ:BIND) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News
06/01/16 11:20 AMStrong Sell Calls Count For BIND Therapeutics, Inc. (NASDAQ:BIND) At 0 - Investor Newswire - Strong Sell Calls Count For BIND Therapeutics, Inc. (NASDAQ:BIND) At 0Investor NewswireThe Sell calls on BIND Therapeutics, Inc. (NASDAQ:BIND) were 0. Two months earlier 1 were the Strong Buy calls whereas Strong Sell calls were 0. During this period, the hold calls were 3. The buy recommendations were 0 and sell calls count was 0.and more »
05/31/16 02:52 PMShare Rating Focus on BIND Therapeutics, Inc. (NASDAQ:BIND) - HNN - Share Rating Focus on BIND Therapeutics, Inc. (NASDAQ:BIND)HNNThis stock research may entail following what professional equity analysts think about the company. Presently, Wall Street analysts have given a consensus stock rating of 2.5 on shares of BIND Therapeutics, Inc. (NASDAQ:BIND). Covering analysts will ...and more »
05/30/16 08:58 PMBrokerages gives Consensus Recommendation of “Hold” to BIND Therapeutics Inc (NASDAQ:BIND) - Let Me Know About This - Brokerages gives Consensus Recommendation of “Hold” to BIND Therapeutics Inc (NASDAQ:BIND)Let Me Know About ThisBIND Therapeutics logo BIND Therapeutics Inc (NASDAQ:BIND) has received an average recommendation of “Hold” from the six ratings firms that are presently covering the stock. Four equities research analysts have rated the stock with a hold ...
05/27/16 01:19 PMWhich way BIND Therapeutics, (NASDAQ:BIND) earnings may go - iStreetWire - iStreetWireWhich way BIND Therapeutics, (NASDAQ:BIND) earnings may goiStreetWireBIND Therapeutics, Inc. (BIND) added 2.38% to reach at the floor price of $0.43 as the company is set to share its next quarterly earnings on August 04, 2016. BIND stock trades between $0.41 and $0.45 before the earnings release. Let's take a closer ...
05/27/16 01:19 PMBroker Roundup For BIND Therapeutics, Inc. (NASDAQ:BIND) - Share Trading News - Broker Roundup For BIND Therapeutics, Inc. (NASDAQ:BIND)Share Trading News12/04/2014 – BIND Therapeutics, Inc. was downgraded to “neutral” by analysts at Credit Suisse. They now have a USD 10 price target on the stock. The share price of BIND Therapeutics, Inc. (NASDAQ:BIND) was down -9.35% during the last trading session, ...and more »
05/20/16 01:23 PMStock Runners: BIND Therapeutics, Inc. (NASDAQ:BIND), Sanchez Energy Corporation (NYSE:SN), LendingClub ... - KC Register - Stock Runners: BIND Therapeutics, Inc. (NASDAQ:BIND), Sanchez Energy Corporation (NYSE:SN), LendingClub ...KC RegisterOn 5 May, BIND Therapeutics, Inc. (NASDAQ:BIND) announced a research collaboration with Affilogic, a privately held biotechnology company developing affinity proteins called Nanofitins® that selectively bind and interact with identified targets. Under ...
05/20/16 01:23 PMStock for Investors: BIND Therapeutics Inc (NASDAQ:BIND) - News Oracle - Stock for Investors: BIND Therapeutics Inc (NASDAQ:BIND)News OracleBy looking at BIND Therapeutics Inc (NASDAQ:BIND) YTD (year to date) performance, the stock shows Negative value of -80.35%. If the YTD value is Negative, it means that the stock is trading poorly. If the YTD value is Positive, this means the stock is ...and more »
05/20/16 01:23 PMBIND Therapeutics Provides Update on Chapter 11 Proceedings and Announces Agreement with Hercules ... - Business Wire (press release) - Street RegisterBIND Therapeutics Provides Update on Chapter 11 Proceedings and Announces Agreement with Hercules ...Business Wire (press release)CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced an agreement has been reached with its secured ...BIND Therapeutics Gains 8.5% After Reaching Agreement with Lender Hercules Capital (NASDAQ:BIND)Sonoran Weekly ReviewBiotech Stocks Worth Chasing: BIND Therapeutics, Inc. (BIND), Array BioPharma Inc. (ARRY)ZergwatchThe Insider Activity Don't Lie: BIND Therapeutics, Inc. (NASDAQ:BIND)Street Registerall 5 news articles »
05/19/16 06:02 PMETF’s with exposure to BIND Therapeutics, Inc. : May 19, 2016 -
05/19/16 03:12 PMBIND THERAPEUTICS, INC Files SEC form 8-K, Other Events -
05/19/16 12:59 PMHot Alert: BIND Therapeutics, Inc. (NASDAQ:BIND), Sanchez Energy Corporation (NYSE:SN), LendingClub ... - KC Register - Hot Alert: BIND Therapeutics, Inc. (NASDAQ:BIND), Sanchez Energy Corporation (NYSE:SN), LendingClub ...KC RegisterOn 5 May, BIND Therapeutics, Inc. (NASDAQ:BIND) announced a research collaboration with Affilogic, a privately held biotechnology company developing affinity proteins called Nanofitins® that selectively bind and interact with identified targets. Under ...
05/19/16 12:59 PMBRIEF-Bind Therapeutics provides update on Chapter 11 proceedings - Reuters - BRIEF-Bind Therapeutics provides update on Chapter 11 proceedingsReutersMay 19 Bind Therapeutics Inc : * Bind therapeutics provides update on chapter 11 proceedings and announces agreement with Hercules Technology III, L.P.. * Has agreed, among other things, to pay-down $4 million in principal on existing principal loan ...
05/19/16 12:59 PMBIND Therapeutics (BIND) Provides Update on Chapter 11 Proceedings, Enters Agreement with Hercules Technology ... - StreetInsider.com - BIND Therapeutics (BIND) Provides Update on Chapter 11 Proceedings, Enters Agreement with Hercules Technology ...StreetInsider.comBIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced an agreement has been reached with its secured lender Hercules Technology III, L.P., ...Biotech Stocks Worth Chasing: BIND Therapeutics, Inc. (BIND), Array BioPharma Inc. (ARRY)Zergwatchall 2 news articles »
05/19/16 07:32 AMBIND Therapeutics Provides Update on Chapter 11 Proceedings and Announces Agreement with Hercules Technology III, L.P. - [at noodls] - May 19, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced an agreement ...
05/18/16 12:04 PMBIND THERAPEUTICS, INC Financials -
05/17/16 11:20 AMBIND Therapeutics, Inc. :BIND-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/11/16 06:55 AMConsensus Rating Review for BIND Therapeutics, Inc. (NASDAQ:BIND) - B.O.D.Y Confidential - Consensus Rating Review for BIND Therapeutics, Inc. (NASDAQ:BIND)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 2.5 on shares of BIND Therapeutics, Inc. (NASDAQ:BIND). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell ...and more »
05/11/16 06:55 AMWatch-list of Hot Stocks: Allergan plc. (NYSE:AGN) , BIND Therapeutics, Inc. (NASDAQ:BIND) - Is stories - Is storiesWatch-list of Hot Stocks: Allergan plc. (NYSE:AGN) , BIND Therapeutics, Inc. (NASDAQ:BIND)Is storiesAllergan plc. (NYSE:AGN) increased +5.98% to $213.71 while traded 6.46 million shares on 5/9/2016. The stock price negotiated for value between $206.15 to $217.00 in recent trading session. During the past 52 weeks, the stock's price witnessed a ...and more »
05/11/16 06:55 AMCrowd Views on: BIND Therapeutics Inc (NASDAQ:BIND) - The Point Review - NewsWay 21Crowd Views on: BIND Therapeutics Inc (NASDAQ:BIND)The Point ReviewShare of BIND Therapeutics Inc (NASDAQ:BIND) traded on -18.67 percent below secure line at 11:23AM EDT in order to take the company's stock at the price of $0.464. At the time of writing the stock exchanged hands 617,666.00 shares versus average ...BIND Therapeutics Reports First Quarter 2016 Financial Results and Provides Business UpdateBusiness Wire (press release)Biotech stocks for your portfolio: Celldex Therapeutics, Inc. (CLDX), BIND Therapeutics, Inc. (BIND)ZergwatchBIND Therapeutics Inc (NASDAQ:BIND) Receives $6.00 Consensus PT from BrokeragesNewsWay 21Sonoran Weekly Review -NYSE Journal (press release) -Web Breaking Newsall 16 news articles »
05/10/16 07:17 AMBRIEF-Bind Therapeutics Q1 loss per share $0.61 - May 9 Bind Therapeutics Inc : * Qtrly revenue $1.98 million versus $4.4 million * Qtrly loss per share $0.61 * Q1 earnings per share view $-0.55, revenue view $3.8 million -- Thomson Reuters I/B/E/S * Bind Therapeutics reports first quarter 2016 financial ...
05/10/16 07:17 AMBIND Therapeutics Inc Earnings Call (Q1 2016) - BIND Therapeutics, Inc., a biotechnology company, develops novel targeted therapeutics primarily for the treatment of cancer in the United States and Russia. It is developing ACCURINS with specific pharmaceutical properties intended to target tumors at ...
05/10/16 07:00 AMData Published in Journal of Controlled Release Demonstrate Flexibility of ACCURINS® to Encapsulate a Broad Range of Physically and Chemically Diverse Payloads with High Encapsulation Efficiency and Tunable Release Kinetics - [Business Wire] - BIND Therapeutics, Inc. , a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced the publication of detailed methods for its hydrophobic ion pairing approach that can be applied to a wide range of ionizable molecules, greatly increasing the diversity of payloads that can be encapsulated in ACCURINS®.
05/09/16 11:54 AMBIND THERAPEUTICS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex -
05/09/16 07:30 AMBIND Therapeutics Inc Earnings Call scheduled for 8:30 am ET today -
05/09/16 07:16 AMBRIEF-Bind Therapeutics Q1 loss per share $0.61 - Reuters - BRIEF-Bind Therapeutics Q1 loss per share $0.61ReutersMay 9 Bind Therapeutics Inc : * Qtrly revenue $1.98 million versus $4.4 million. * Qtrly loss per share $0.61. * Q1 earnings per share view $-0.55, revenue view $3.8 million -- Thomson Reuters I/B/E/S. * Bind Therapeutics reports first quarter 2016 ...
05/09/16 06:23 AMBind Therapeutics reports 1Q loss -
05/09/16 06:16 AMBIND Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update - [at noodls] - May 9, 2016 Company does not anticipate disruption in operations under Chapter 11 protection CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine company ...
05/09/16 06:07 AMQ1 2016 BIND Therapeutics Inc Earnings Release - Before Market Open -
05/07/16 07:00 AMBIND Therapeutics Announces Collaboration with Affilogic to Provide BIND with Access to Targeting Ligands that are ... - Business Wire (press release) - Web Breaking NewsBIND Therapeutics Announces Collaboration with Affilogic to Provide BIND with Access to Targeting Ligands that are ...Business Wire (press release)CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced a research collaboration with Affilogic, a privately ...Stock's Overselling Recap: BIND Therapeutics Inc (NASDAQ:BIND)The Point ReviewCurrent Price Targets For BIND Therapeutics, Inc. (NASDAQ:BIND)Risers & FallersBind Therapeutics Incorporated (NASDAQ:BIND) Sellers Increased By 0.17% Their ShortsFranklin IndependentWeb Breaking News -Street Registerall 11 news articles »
05/06/16 07:28 AMIs a Surprise Coming for BIND Therapeutics (BIND) This Earnings Season? - Nasdaq - Is a Surprise Coming for BIND Therapeutics (BIND) This Earnings Season?NasdaqGiven that BIND has a Zacks Rank #3 (Hold) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Clearly, recent earnings estimate revisions suggest that good things are ahead for BIND Therapeutics, and that a ...and more »
05/06/16 07:28 AMTwo Biotech stocks to Watch: BIND Therapeutics, Inc. (NASDAQ:BIND) , Becton, Dickinson and Company (NYSE:BDX) - Is stories - Is storiesTwo Biotech stocks to Watch: BIND Therapeutics, Inc. (NASDAQ:BIND) , Becton, Dickinson and Company (NYSE:BDX)Is storiesBIND Therapeutics, Inc. (NASDAQ:BIND) increased +56.63% to $0.65 while traded 8.45 million shares on 5/5/2016. The stock price negotiated for value between $0.42 to $0.74 in recent trading session. During the past 52 weeks, the stock's price witnessed ...and more »
05/06/16 07:28 AMBIND Therapeutics (BIND) Enters Research Collaboration with Affilogic; Will Utilize Nanofitins - StreetInsider.com - Web Breaking NewsBIND Therapeutics (BIND) Enters Research Collaboration with Affilogic; Will Utilize NanofitinsStreetInsider.comBIND Therapeutics, Inc. (NASDAQ: BIND) announced a research collaboration with Affilogic, a privately held biotechnology company developing affinity proteins called Nanofitins® that selectively bind and interact with identified targets. Under terms of ...Stock's Overselling Recap: BIND Therapeutics Inc (NASDAQ:BIND)The Point ReviewCurrent Price Targets For BIND Therapeutics, Inc. (NASDAQ:BIND)Risers & FallersBind Therapeutics Incorporated (NASDAQ:BIND) Sellers Increased By 0.17% Their ShortsFranklin IndependentLexology (registration) -Web Breaking News -Street Registerall 11 news articles »
05/06/16 07:28 AMNoteworthy Analysts Suggestions: BIND Therapeutics, Inc. (NASDAQ:BIND) , Eli Lilly and Company (NYSE:LLY) - Street Updates - Noteworthy Analysts Suggestions: BIND Therapeutics, Inc. (NASDAQ:BIND) , Eli Lilly and Company (NYSE:LLY)Street UpdatesBIND Therapeutics, Inc. (NASDAQ:BIND) accumulated +56.63%, closing at $0.65 after floating between $0.42 and $0.74. The company has market capitalization of $13.51M. It has twelve month low of $0.35 and twelve month high of $6.49. The recent traded ...and more »
About BIND Therapeutics

BIND Therapeutics logoBIND Therapeutics, Inc. is a clinical-stage nano-medicine platform company. The Company is engaged in developing a pipeline of Accurins. The Company utilizes its Medicinal Nano-engineering platform to develop a pipeline of Accurins in oncology. The Company's products include BIND-014 and BIND-510. The Company's lead drug candidate BIND-014 is a prostate-specific membrane antigen (PSMA)-targeted Accurin that contains docetaxel, a clinically validated cancer chemotherapy drug. PSMA is a clinically validated tumor marker expressed on prostate cancer cells and the blood vessels of many types of non-prostate solid tumors. It has completed a Phase I clinical trial evaluating BIND-014 in patients with advanced and metastatic solid tumors. The Company's product candidate BIND-510 is also a PSMA-targeted Accurin containing vincristine. BIND-510 is designed to concentrate high levels of vincristine in tumors while limiting exposure to healthy tissue.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BIND
  • CUSIP:
Key Metrics:
  • Previous Close: $0.38
  • 50 Day Moving Average: $0.41
  • 200 Day Moving Average: $1.45
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $7.94M
  • Current Quarter EPS Consensus Estimate: $-1.47 EPS
Additional Links:
BIND Therapeutics (NASDAQ:BIND) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha